Loading…
We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more
Head-to-head evidence comparison — which supplement is right for you?
Berberine wins 2 of 3 categories. Both are solid choices — the best pick depends on your specific goals.
Verdict
Likely helps
12 of 16 studies with measurable effects showed benefit.
Top outcomes
Verdict
Likely helps
8 of 11 studies with measurable effects showed benefit.
Top outcomes
Shared outcomes (1)
Outcomes where both Berberine and D-Mannose have evidence — compare verdict strength side-by-side.
500mg 2-3x daily (1000-1500mg total)
With meals, Split into 2-3 doses
Berberine HCl capsules
2g daily for prevention; 1.5-2g every 2-3 hours for acute symptoms
On empty stomach with water, Before bed (urine stays in bladder longer)
Pure D-Mannose powder
4-12 weeks
8-12 weeks
First 2 weeks
If on diabetes medications
Ongoing prevention
24-48 hours
Clinical Efficacy of Curcumin, Resveratrol, Silymarin, and Berberine on Cardio-Metabolic Risk Factors Among Patients With Type 2 Diabetes Mellitus: A Systemic Review and Bayesian Network Meta-Analysis
Phytotherapy research : PTR (2025) · Meta analysis · n=1337
For HbA1c, silymarin was more effective than resveratrol (MD -2.08, 95%Cl -3.50 to -0.72) (P < 0.05).
Effects of berberine and barberry on selected inflammatory biomarkers in adults: A systematic review and dose-response meta-analysis of randomized clinical trials
Phytotherapy research : PTR (2023) · Meta analysis · n=1600
In addition, the non-linear analysis showed a significant lowering effect of berberine/barberry on IL-6 and TNF-α levels in doses <1000 mg/day and less than 5 weeks of intervention.
Berberine Ursodeoxycholate for the Treatment of Type 2 Diabetes: A Randomized Clinical Trial
JAMA network open (2025) · Rct · n=113
The study included 113 patients with T2D (mean [SD] age, 54.3 [10.6] years; 72 male [63.7%]) who were randomized.
Nonantibiotic prophylaxis for urinary tract infections: a network meta-analysis of randomized controlled trials
Infection (2025) · Meta analysis · n=10495
Nearly 80% of the RCTs utilized double-blind or triple-blind designs.
Efficacy of D-mannose as prophylaxis of recurrent urinary tract infection: a systematic review and meta-analysis of randomized controlled trials
Jornal brasileiro de nefrologia (2025) · Meta analysis · n=1167
We included 6 RCTs comprising 1,167 participants, of whom 534 received D-mannose and 521 (97.6%) were women.
d-Mannose for Prevention of Recurrent Urinary Tract Infection Among Women: A Randomized Clinical Trial
JAMA internal medicine (2024) · Rct · n=7591
Of 598 women eligible (mean [range] age, 58 [18-93] years), 303 were randomized to d-mannose (50.7%) and 295 to placebo (49.3%).
Based on meta-analyses showing FPG reduction of 0.59-0.82 mmol/L and HbA1c reduction of 0.63%. Studies primarily used berberine HCl with low bioavailability. Effects require divided doses and may take 8-12 weeks.
Based on meta-analysis of 6 RCTs (n=1,167) showing mixed results - one large meta-analysis found no significant reduction vs control. Evidence quality limited by heterogeneity in study designs. Conservative effectiveness estimates due to conflicting findings.
AI-estimated from published studies. Interpret as directional guidance.
Berberine has a higher evidence score (9/10 vs 8.5/10) and wins in 2 of 3 categories.
No known interactions between Berberine and D-Mannose have been documented in our database. However, always consult a healthcare provider before combining supplements.